Clinical Trial Update: CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients [Phase 2]

View source ↗

Summary

Phase 2 trial investigating CTA expression/methylation and response to pembrolizumab in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Medical University of Vienna | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN